Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21867939 | 0.88 | DRD1 (0.46) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL28026555 | 0.85 | DRD1 (0.49) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL30412133 | 0.84 | DRD1 (0.72) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL2200119 | 0.84 | DRD1 (0.72) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL29620958 | 0.84 | DRD1 (0.72) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL29253292 | 0.84 | DRD1 (0.57) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL22841575 | 0.76 | FTO (0.36) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL14073339 | 0.74 | CYP3A4 (0.43) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL24905071 | 0.72 | DRD1 (0.42) | DRD1CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL24905030 | 0.72 | DRD1 (0.42) | DRD1CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979339-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-2035408-A1 | SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008000922-A1 | SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082329-A1 | Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | CHUK, BRAF, CNKSR1 | DRD1 4616/4885CYP3A4 3710/4885TDP1 1781/4885 |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKAR2B, CDK1, PRKX | DRD1 3476/4885CYP3A4 2122/4885TDP1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.